This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioPlus Acquisition Stock (NASDAQ:BIOS) 30 days 90 days 365 days Advanced Chart Get BioPlus Acquisition alerts:Sign Up Key Stats Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,636 shsAverage Volume122,781 shsMarket Capitalization$209.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Read More… Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOS Stock News HeadlinesUpstream Bio Pursues $100 Million IPO Plan With Encouraging Trial ResultsSeptember 25, 2024 | seekingalpha.comPayMate Plans to Acquire DigiAsia BiosSeptember 24, 2024 | marketwatch.comBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.June 3, 2025 | Stansberry Research (Ad)Gigabyte details BIOS roll-out plan to neutralize Sinkclose vulnerability — eligible AMD CPUs should be patched by end of the monthAugust 24, 2024 | yahoo.comMadison's Mirus Bio to be acquired by MilliporeSigma for $600 millionMay 28, 2024 | bizjournals.comBiogen enters deal to acquire HI-Bio for $1.8bnMay 23, 2024 | msn.comBiogen’s Strategic Acquisition of HI-Bio and Diversification into Orphan Drug Market Prompt ‘Buy’ RatingMay 22, 2024 | markets.businessinsider.comBiogen to buy San Francisco startup developing a drug for kidney disease for $1.2BMay 22, 2024 | bizjournals.comSee More Headlines BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an IPO on Friday, December 3rd 2021. The company issued 18,000,000 shares at a price of $10.00 per share. Cantor served as the underwriter for the IPO. What other stocks do shareholders of BioPlus Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPlus Acquisition investors own include TransMedics Group (TMDX), Deciphera Pharmaceuticals (DCPH) and BioMarin Pharmaceutical (BMRN). Company Calendar Today6/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.10 million OptionableNot Optionable Beta0.01 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:BIOS) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPlus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
